Dr. Dennis Arthur Ausiello, M.D. is the Jackson Distinguished Professor of Clinical Medicine at Harvard Medical School. Dr. Ausiello is a Strategic Advisor of Proventys, Inc. He is Physician-in-Chief Emeritus at Massachusetts General Hospital. Dr. Ausiello serves as an Advisor of InCube Labs, LLC. Dr. Ausiello has been Advisor at PureTech Health PLC since November 30, 2015. He served as the Physician-in-Chief of the Department of Medicine at The General Hospital Corporation (Massachusetts General Hospital (MGH)) since 1996 and Chief of Medical Services from 1996 to April 2013. He has been a Director and Member of the Scientific Advisory Board at Alnylam Pharmaceuticals, Inc. since April 2012. Dr. Ausiello serves as a Director at Broad Institute and Taris Biomedical, Inc. He serves as a Director of LiRIS Biomedical, Inc. and EnBiotix, Inc. He has been a Director of Tarveda Therapeutics, Inc. (alternate name: Blend Therapeutics, Inc.) since January 2015 and Seres Therapeutics, Inc. since April 2015. Dr. Ausiello serves as a Member of Board of Advisors at InCube Ventures, LLC. He serves as a Member of the Scientific Advisory Board at Verily Life Sciences LLC and Boston BioCom LLC. He serves as the Director of the Center for Assessment Technology and Continuous Health (CATCH). Dr. Ausiello serves as a Member of the Advisory Board at Polaris Partners. He was an Independent Director of Pfizer Inc., from December 1, 2006 to April 25, 2019 and served as its Lead Independent Director until 2018. He served as Member of Scientific Advisory Board at BIND Therapeutics, Inc. (alternate name, BIND Biosciences, Inc.). He served as a Director of Microchips Biotech, Inc. (MicroCHIPS, Inc.). He served as Member of the Scientific Advisory Board at Pulmatrix, Inc., Tarveda Therapeutics, Inc. and Promedior, Inc. Dr. Ausiello was a Fellow of the American Academy of Arts and Sciences.
Country: United States